Predictive Oncology Introduces New Technology For Expressing Functional And Stable G-Protein Coupled Receptors (GPCRs)
Portfolio Pulse from Benzinga Newsdesk
Predictive Oncology has introduced a new technology called 'Membrane Protein Factory' for expressing functional and stable G-Protein Coupled Receptors (GPCRs). The company has filed for intellectual property protection for this technology, which aims to produce purified and biologically active membrane proteins for drug development. The annual US GPCR market was valued at nearly $3.5 billion in 2022 and is expected to grow more than 5% annually through 2030.
June 11, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Predictive Oncology has introduced a new technology for expressing functional and stable GPCRs and filed for intellectual property protection. This could significantly impact the company's position in the growing GPCR market, valued at $3.5 billion in 2022.
The introduction of the 'Membrane Protein Factory' and the filing for intellectual property protection could enhance Predictive Oncology's competitive edge in the GPCR market. Given the market's significant size and growth rate, this development is likely to positively impact POAI's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100